Navigation Links
Gene therapy slows progression of fatal neurodegenerative disease in children
Date:5/13/2008

New Rochelle, NY, May 13, 2008Gene therapy to replace the faulty CLN2 gene, which causes a neurodegenerative disease that is fatal by age 8-12 years, was able to slow significantly the rate of neurologic decline in treated children, according to a paper published online ahead of print in the May 2008 issue (Vol. 19 No. 5) of Human Gene Therapy, a peer-reviewed journal published by Mary Ann Liebert, Inc. The paper is available free online at www.liebertpub.com/hum

Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL) is an autosomal recessive genetic disorder that causes degeneration of the central nervous system. It is a form of Batten disease, a group of lysosomal storage disease in which a lipofuscin-like material is not broken down and accumulates in neurons, causing cognitive impairment, visual failure, seizures, and progressive deterioration of motor function.

Ronald Crystal and colleagues from Weill Cornell Medical College (New York, NY), describe a study conducted in 10 children with LINCL who received gene therapy to replace the defective CLN2 gene via administration of human CLN2 carried in an adeno-associated virus (AAV). In the paper entitled Treatment of Late Infantile Neuronal Ceroid Lipofuscinosis with CNS Administration of a Serotype 2 Adeno-associated virus expressing the CLN2 cDNA, the authors report that over an 18-month period, assessment using a neurologic rating scale demonstrated significant slowing of disease progression in the treated, compared to the untreated children. On the basis of these findings, the authors proposed that additional studies to assess the safety and efficacy of AAV-mediated gene therapy for LINCL be pursued.

Although the treatment was associated with some serious adverse events in some patients, these were not unequivocally attributable to the gene therapy vector.

This clinical trial is an important step toward the development of treatments for this group of underserved i
'/>"/>

Contact: Vicki Cohn
vcohn@liebertpub.com
914-740-2156
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert

Page: 1 2

Related biology news :

1. UC Davis stem researchers demonstrate safety of gene therapy using adult stem cells
2. Cell-based therapy shows promise in patients with Parkinsons disease
3. Cancer immunotherapy shows long-term promise in lung cancer
4. Effective cancer immune therapy through order in the blood vessels
5. New chemotherapy combo produces side effects, but no extra efficacy, in early breast cancer patients
6. Biomarkers allow doctors to match therapy to patient
7. MU researcher links hormone replacement therapy to breast cancer
8. Potential new target for multiple sclerosis therapy
9. Umbilical cord blood cell therapy may reduce signs and symptoms of Alzheimers disease
10. Umbilical cord blood cell therapy in an animal model of Alzheimers disease
11. Tumor-targeting viral therapy slows neuroblastoma, malignant peripheral nerve sheath tumors

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...tate University assistant professors recently rece...(NSF) to continue research beneficial to understan...000. , Christopher Blackwood, assistant professo...arded grants to support two separate research proj...tter Decomposer Communities and Functions from the...
(Date:11/24/2009)...ence is opening new doors to understanding how sou...aring of a marine mammal or if they hear it at al...ay scanners that NASA uses to detect flaws in the ... allowing scientists to peek inside the giant head...e-dimensional replicas of a whale,s hearing anatom...
(Date:11/24/2009)...nd the American College of Medical Toxicology (ACM...publication of the Journal of Medical Toxicology ...g in March 2010. It was previously published by t...rnal of Medical Toxicology , an international, pee...science and practice of medical toxicology. The q...
Breaking Biology News(10 mins):Kent State University professors focus research on the environment with grants totaling $890,000 2Rocket science leads to new whale discovery 2Springer and the American College of Medical Toxicology to work together 2Strep B Seems to Trick Immune System 51448 1Bathtub Accidents Injure 43 000 U S Kids Each Year 51446 1Bathtub Accidents Injure 43 000 U S Kids Each Year 51446 2National Trauma Institute Announces 15th Annual Trauma Symposium in San Antonio August 31 September 1 51444 1National Trauma Institute Announces 15th Annual Trauma Symposium in San Antonio August 31 September 1 51444 2
...ered that two microRNA (miRNA) molecules help cont...of B-cell chronic lymphocytic leukemia (B-CLL), th...r findings, published in the December 15 issue of ...ing as powerful regulators of gene expression in c... drug treatment, the investigators say. , In t...
...blem could be eliminated simply by dusting slag on...& Industry, the magazine of the SCI. , In the ...f damage annually. , Researcher David Cowen and...t applying slag to wheat growing in greenhouses ha...orporate the silica and express it as spiky struct...
... of plants to defend themselves by accumulating hi...me insects, and that such adaptation potentially e...ites may in turn evolve to deal with high levels o...zabeth Pilon-Smits of Colorado State University an...rnia, Berkeley, appear in the November 21st issue ...
Other Biology News:Pair of microRNA molecules controls major oncogene in most common leukemia 2New moth variety disarms plants guarded by selenium 2
(Date:11/24/2009)...24 NeurogesX, Inc. (Nasd...n developing and commercializing novel pain manage...no, President and Chief Executive Officer, is sche...Health Care Conference, to be held December 1-2, 2...York. ,, Mr. DiTonno and Stephen Ghiglieri, Ch...
(Date:11/24/2009)...ly approved the Promega PowerPlex 16 HS System for...g DNA records for the National DNA Index System. ...-- The FBI recently approved the Promega PowerPle...cipating in, or generating DNA records for, the Na...tains more than seven million profiles and has ass...
(Date:11/24/2009)...Newswire-FirstCall/ -- Shire plc (LSE: SHP,NASDAQ... company, today,announced that it has submitted a ...rase alfa, the company,s enzyme replacement therap...er disease. This is the third marketing,applicatio...with previous,submissions in the United States and...
(Date:11/24/2009)...r 24 Health Robotics today announc... with a group of selected,investors. This recently...he,name Health Robotics Canada, Inc. and will mark...m of the Future concept, which includes the,revolu...T(TM), and OMM(TM).,Health Robotics Canada Inc. wi...
Breaking Biology Technology:NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3NDIS Approval of Promega PowerPlex Kit Clears Path for More DNA Profiles to be Added to U.S. Database 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 4Health Robotics Continues its Global Expansion With December 09 ASHP's Launch of Joint Venture in Canada 2Health Robotics Continues its Global Expansion With December 09 ASHP's Launch of Joint Venture in Canada 3
...12 MAP,Pharmaceuticals, Inc. (Nasdaq: MAPP ) to...e 3 clinical programs, Unit Dose Budesonide (UDB) ... treatment of migraine. For UDB, all,patients hav...itial Phase 3,clinical trial, and for MAP0004, the...in its initial Phase 3 clinical trial by the end o...
...of Schedule , , ST. LOUIS and RICHMOND, Calif., ... ) today announced it has reached a major producti...h Sigma-Aldrich Corporation (Nasdaq: SIAL ) to c...for research applications. The milestone triggers ...ng this production milestone more than one year ah...
...sset, Inc. (Nasdaq: VRUS ) announced today that ...reed with the FDA on the final design for a phase ...atitis C (HCV), slated to initiate in the first qu...8 is advancing into a large phase 2b trial," state...ical Officer. "R7128 is the most advanced nucleosi...
Other Biology Technology:MAP Pharmaceuticals Provides Update on Progress of Two Phase 3 Clinical Programs 2MAP Pharmaceuticals Provides Update on Progress of Two Phase 3 Clinical Programs 3Sigma-Aldrich and Sangamo BioSciences Announce the Achievement of Key Throughput Milestone in Research Reagents Agreement 2Sigma-Aldrich and Sangamo BioSciences Announce the Achievement of Key Throughput Milestone in Research Reagents Agreement 3Sigma-Aldrich and Sangamo BioSciences Announce the Achievement of Key Throughput Milestone in Research Reagents Agreement 4Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients 2Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients 3Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients 4Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients 5
Rabbit Anti-Mouse SHPRH Polyclonal Antibody, Unconjugated from IMGENEX
Rabbit Anti-PI3K p110 delta (Poly6049) Polyclonal Antibody, Unconjugated from BioLegend
Rabbit Anti-Tyrosine Hydroxylase, phospho (Ser40) Polyclonal Antibody, Unconjugated from IMGENEX
NF kappa B Related Sampler Kit from BD Biosciences Pharmingen
Biology Products: